Related Experiment Video
Updated: May 21, 2026
05:23
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon: An
Romaric De Manfouo Tuono1,2, Josué Louokdom Simo1, Paule Rita Ngamgwe Tchouanmo1
1Higher Institute of Health Sciences, Université Des Montagnes, Bangangté, Cameroon, udesmontagnes.org.
Advances in Hematology
|May 20, 2026
Summary
Sickle cell disease patients frequently face thrombotic risk due to decreased physiological coagulation inhibitors. Early monitoring of these inhibitors is crucial for preventing cardiovascular complications in this population.
Area of Science:
- Hematology
- Vascular Biology
- Clinical Medicine
Background:
- Thrombotic risk, the likelihood of blood clot formation, is influenced by physiological coagulation inhibitors.
- Sickle cell disease presents multiple factors that can initiate thrombosis, including vascular inflammation and altered blood flow.
- Understanding the interplay between coagulation inhibitors, inflammation, and thrombotic risk is critical in managing sickle cell disease.
Purpose of the Study:
- To evaluate the levels of physiological coagulation inhibitors in sickle cell disease patients.
- To assess the association between inflammation markers and thrombotic risk in this cohort.
- To determine the thrombotic risk in patients with sickle cell disease.
Main Methods:
- An analytical cross-sectional study was conducted involving 150 homozygous sickle cell patients.
- Blood samples were analyzed for hemogram, protein C, protein S, antithrombin activity, C-reactive protein (CRP), and interleukin-6 (IL-6).
- Statistical analysis was performed using R software to evaluate the data.
Main Results:
- A significant thrombotic risk (65.34%) was observed in sickle cell patients, associated with high frequencies of anemia, leukocytosis, and thrombocytosis.
- Elevated inflammatory markers (CRP and IL-6) were significantly higher in patients with thrombotic risk.
- Decreased levels of protein C, protein S, and antithrombin were noted in patients with thrombotic risk, with decreased protein S identified as a predictive factor.
Conclusions:
- Sickle cell disease patients exhibit a high frequency of thrombotic risk linked to reduced physiological coagulation inhibitors.
- Inflammation plays a significant role in the thrombotic risk associated with sickle cell disease.
- Systematic assessment of coagulation inhibitors is recommended for cardiovascular disease prevention in sickle cell patients.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...